

Severe In-Stent Restenosis due to Two Stent Layers: A Case Report

Pavel Somov¹, Dmitriy Marchak¹, Arkhip Matusov¹

¹Pirogov's National Medical Surgical Center, Moscow, Russian Federation

Abstract

Background: The prevalence of in-stent restenosis is around 3-10%. One treatment option for restenosis is implantation of another drug eluting stent, the so-called “sandwich strategy”. Multiple stent layers can potentially reduce the penetration of antiproliferative drugs into the vessel wall, thereby minimizing the effect of the drug. In this clinical case, we encountered restenosis after a previously implanted stent for treatment of restenosis.

Case presentation: A 73-year-old female with previous history of RCA stenting in 2019 due to myocardial infarction. In 2020, RCA restenosis was identified and RCA PCI was performed (Supraflex 2.75x28mm, XienceXpedition 3.5x38mm). The current hospitalization was associated with a recurrence of dyspnea on exertion. Coronary angiography revealed an 80% restenosis of the RCA. A decision was made to perform ultra-high-pressure balloon for this lesion. A stent-boost image was obtained showing stent deformation. Balloon angioplasty was performed using a 3.5x15mm ultra-high-pressure balloon OPN NC (SIS Medical, Switzerland) at 40 atm. Control angiography showed a restoration of vessel lumen. IVUS showed minimal lumen area (MLA) of 8.37 mm². Six months later, because of a recurrence of dyspnea on exertion, a myocardial scintigraphy was performed, which revealed an ischemic zone of 20-25%. Based on these results, angiography was performed which identified recurrent restenosis in the same segment. IVUS-guided angioplasty with a 4.0x15mm OPN NC in combination with a 4.0x30mm Agent drug-coated balloon (DCB) was performed with inflation at 6 atm for 60 seconds. This resulted in good angiographic results, with an MLA of 9.76mm² and optimal stent expansion throughout.

Conclusion: Treatment of patients with restenosis remains a challenging task. Intravascular imaging is a fundamental factor in restenosis management, allowing determination of restenosis type and selection of optimal treatment strategy to achieve satisfactory results and reduce the risk of repeat interventions. Therefore, the combination of intravascular imaging and dedicated devices is strongly suggested for a more standardized approach for in-stent restenosis.

Key-words In-stent restenosis, Multiple stent layers, Intravascular image

Introduction

Despite the use of 2nd and 3rd generation drug-eluting stents (DES), the risk of developing in-stent restenosis (ISR) remains at 3-10%¹. One treatment option for restenosis is implantation of another drug eluting stent, the so-called “sandwich strategy”². However, a large amount of neointimal hyperplasia and multiple stent layers can potentially reduce the penetration of antiproliferative drugs into the vessel wall, thereby minimizing the effect of the drug³⁻⁵. In this clinical case, we encountered an ISR after a previously implanted stent for treatment of an ISR.

Clinical Case

A 73-year-old female patient was admitted to our center. From the medical history, it was known that in 2017 coronary artery bypass grafting was recommended due to three-vessel coronary disease, which the patient refused. In 2019, myocardial infarction and percutaneous coronary

intervention (PCI) of the right coronary artery (RCA) and left anterior descending artery (LAD) were performed. In 2020, RCA ISR was identified and PCI was performed on the RCA (Supraflex 2.75x28mm, XienceXpedition 3.5x38mm). The current hospitalization was associated with a recurrence of complaints of dyspnea on exertion. Coronary angiography was performed, revealing 80% ISR of the RCA (Figure 1). A decision was made to perform ultra-high-pressure balloon angioplasty for this lesion. Using a right radial approach with a 6F JR4 Launcher (Medtronic, USA), a Rinato guidewire (Asahi Intecc, Japan) was advanced into the distal vessel. Intravascular ultrasound (IVUS) examination was performed (Opticross 40, Boston Scientific, USA) (Figure 2). Minimum lumen area was 3.26 mm². A stent-boost image was obtained (Figure 3) showing stent deformation. Balloon angioplasty was performed using 3.0x15mm NC Sprinter (Medtronic, USA), and a 3.5x15mm ultra-high-pressure balloon OPN NC (SIS Medical, Switzerland) at 40 atm. Figure 4 shows balloon expansion in stent-boost mode. Figure 5 demon-



Figure 1. RCA restenosis




Figure 2. IVUS of RCA restenosis




Figure 3. Stent deformation (stent-boost)



Figure 4. Balloon expansion (stent-boost)



Figure 5. Angio result




Figure 6. IVUS control. Minimum lumen area 8.37 mm²

strates control angiography with restoration of vessel lumen. IVUS showed minimum lumen area of 8.37 mm² (Figure 6), with neocalcification area and structures of the two previously implanted stents highlighted in blue. The patient was prescribed atorvastatin 40mg, clopidogrel

75mg, aspirin 100mg, and ezetimibe 10mg. Six months later, cause of a recurrence of dyspnea on exertion a myocardial scintigraphy was performed, which revealed an ischemic zone of 20-25% (Figure 7). Based on these results, angiography was performed which identified recur-




Figure 7. Myocardial scintigraphy




Figure 9. IVUS of restenosis




Figure 8. Recurrent RCA restenosis




Figure 10. OPN 4.0x15




Figure 11. DCB 4.0x30



Figure 12. Angio result

rent ISR in the same segment (Figure 8). After the discussion of the case with our Heart Team we decided to perform drug-coated balloon (DCB) angioplasty. IVUS was performed (Figure 9) and repeat angioplasty with an ultra-high-pressure balloon in combination with a drug-

coated balloon was planned. Balloon angioplasty with 4.0x15mm OPN NC (SIS Medical, Switzerland)(Figure 10) was done. DCB angioplasty with 4.0x30mm Agent (Boston Scientific, USA) (Figure 11) was performed with inflation for 60 seconds at 6 atm. This resulted in good angiographic result (Figure 12), and MLA on IVUS of 9.76 mm² (Figure 13) with optimal stent expansion throughout. At the six-month follow-up, the patient remained angina free.



There are various strategies for treating DES ISR. Repeated DES implantation compared with DCB application has shown the most favorable results regarding repeat restenosis. However, repeated stent implantation leads to reduction in vessel lumen and increases the risk of stent thrombosis⁶⁻⁸. The ISAR-DESIRE 3 study showed comparable results of using DCB and DES in treating restenosis⁹. Upon examination of angiograms with stent-boost mode, we identified stent deformation, therefore we encountered not only restenosis after implantation of two stent layers, but also deformation of the previously stented segment, which further complicated the correction of this lesion. According to the Waksman classification, in this case there is combined restenosis Type 1 (mechanical stent deformation) and Type 5 (2 or more

Treatment of patients with restenosis remains a challenging task. Intravascular imaging is a fundamental factor in restenosis management, allowing determination of restenosis type and selection of optimal treatment strategy to achieve satisfactory results and reduce the risk of repeat interventions. Therefore, the combination of intravascular imaging and dedicated devices is strongly suggested for a more standardized approach for treatment of ISR.



BA indicates balloon angioplasty; CABG, coronary artery bypass graft; CTO, chronic total occlusion; DCB, drug-coated balloon; DES, drug-eluting stent; ELCA: excimer laser coronary atherectomy; ISR, in-stent restenosis; IVL, intravascular lithotripsy; IVUS, intravascular ultrasound; OCT, optical coherence tomography; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; RA, rotational atherectomy; and VBT, vascular brachytherapy.

References

1. Moussa ID, Mohananeey D, Saucedo J, et al. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. *J Am Coll Cardiol*. 2020 Sep 29;76(13):1521-1531. doi: 10.1016/j.jacc.2020.08.002. PMID: 32972528.
2. Alfonso F, Scheller B. Management of recurrent in-stent restenosis: onion skin full metal jacket? *EuroIntervention*. 2013;9:781-5.
3. Maluenda G, Ben-Dor I, Gaglia MA Jr, et al. Clinical outcomes and treatment after drug-eluting stent failure: The absence of traditional risk factors for in-stent restenosis. *Circ Cardiovasc Interv* 2012; 5(1): 12-9. <http://dx.doi.org/10.1161/CIRCINTERVENTIONS.111.963215> PMID: 22319069
4. Mintz GS. Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound. *Am J Cardiol*. 2007;100:26M-35M.
5. Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. *J Geriatr Cardiol JGC*. 2018;15:173-184. doi: 10.11909/j.issn.1671-5411.2018.02.007
6. Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAE-DALUS study). *Eur Heart J*. 2020;41(38):3715-3728. <https://doi.org/10.1093/eurheartj/ehz5947>
7. Kawamoto H, Ruparelia N, Latib A, et al. Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. *J Am Coll Cardiol Interv*. 2015;8(12):1586-1594. <https://doi.org/10.1016/j.jcin.2015.04.032>
8. Alfonso F, Garcia J, Perez-Vizcaino MJ, et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. *J Am Coll Cardiol*. 2009;54(11):1036-1038. <https://doi.org/10.1016/j.jacc.2009.04.082>
9. Giacoppo D, Alvarez-Covarrubias HA, Koch T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. *Eur Heart J*. 2023 Apr 17;44(15):1343-1357. doi: 10.1093/eurheartj/ehad026. PMID: 36807512.
10. Waksman R, Iantorno M. Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach. *Curr Cardiol Rep*. 2018 Oct 22;20(12):140. doi: 10.1007/s11886-018-1076-6. PMID: 30350271.
11. Shah M, Najam O, Bhindi R, et al. Calcium Modification Techniques in Complex Percutaneous Coronary Intervention. *Circ Cardiovasc Interv*. 2021 May;14(5):e009870. doi: 10.1161/CIRCINTERVENTIONS.120.009870. Epub 2021 Jan 14. PMID: 33441017.
12. Shlofmitz, E, Iantorno, M, Waksman, R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review. *Circ Cardiovasc. Interv*. 2019, 12, e007023.

Sažetak

Tesna In-Stent Restenoza uzrokovana postojanjem dva sloja stenta: Prikaz slučaja

Pavel Somov¹, Dmitriy Marchak¹, Arkhip Matusov¹

¹Pirogov's Nacionalni Centar za Hirurgiju, Moskva, Ruska Federacija

Uvod: Prevalenca restenoze u stentu je oko 3-10%. Jedna od opcija lečenja restenoze je implantacija još jednog stenta koji oslobađa lek, takozvana „sendvič strategija“. Višestruki slojevi stenta mogu potencijalno smanjiti prodor antiproliferativnih lekova u zid krvnog suda, čime se minimizira efekat leka. U ovom kliničkom slučaju, naišli smo na restenozu nakon prethodno implantiranog stenta za lečenje restenoze.

Prikaz slučaja: 73-godišnja žena sa prethodnom istorijom stentiranja desne koronarne arterije (DKA) 2019. godine zbog infarkta miokarda. 2020. godine identifikovana je restenoza DKA i izvršena je ponovna perkutana koronarna intervencija (PKI) DKA (Supraflex 2,75x28 mm, XienceXpedition 3,5x38 mm). Aktuelna hospitalizacija je bila povezana sa ponovnom pojavom dispneje pri naporu. Koronarna angiografija je otkrila 80% restenoze DKA. Doneta je odluka da se za ovu leziju izvede stentiranje balonom ultravisokog pritiska. Dobijena je slika stent-busta koja prikazuje deformaciju stenta. Balonska angioplastika je izvršena pomoću balona ultravisokog pritiska 3,5x15 mm OPN NC (SIS Medical, Švajcarska) na 40 atm. Kontrolna angiografija je pokazala restauraciju lumena krvnog suda. Intravenski ultrazvuk (IVUS) je pokazao minimalnu površinu lumena (MLA) od 8,37 mm². Šest meseci kasnije, zbog ponovne dispneje pri naporu, urađena je scintigrafija miokarda, koja je otkrila ishemijsku zonu od 20-25%. Na osnovu ovih rezultata, urađena je ponovna angiografija koja je identifikovala rekurentnu restenozu u istom segmentu. Intravaskularnim ultrazvukom vođena angioplastika sa balonom 4,0x15 mm OPN NC u kombinaciji sa 4,0x30 mm balonom obloženim lekom (DCB) izvršena je sa inflacijom na 6 atm tokom 60 sekundi. Ovo je rezultiralo dobrim angiografskim rezultatima, sa MLA od 9,76 mm² i optimalnim širenjem stenta.

Zaključak: Lečenje pacijenata sa restenozom stenta je i dalje izazovno. Intravaskularni imidžing je fundamentalni faktor u uspešnom lečenju restenoze, omogućavajući određivanje tipa restenoze i izbor optimalne strategije lečenja kako bi se postigli zadovoljavajući rezultati i smanjio rizik od ponovljenih intervencija. Stoga se snažno preporučuje kombinacija intravaskularnog imidžinga i posvećenih uređaja za standardizovani pristup lečenja restenoze u stentu.

KLjučne reči: Restenoza, Slojevi stenta, Intravaskularni imidžing